When most people think about their risk for heart disease, they think about family history. Did a parent or grandparent have a heart attack? Is heart disease “in their genes”? It’s an understandable assumption, and genetics does play a role in cardiovascular risk. But a growing body of research suggests that DNA sequence alone tells only part of the story, and increasingly, scientists believe it may be the smaller part. The rest of the story is largely written in epigenetics, a field of biology that examines how genes are switched on or off, turned up or down, without any change to the underlying DNA code itself.
Cardio Diagnostics Holdings (NASDAQ: CDIO), a medical technology company built around epigenetics-based cardiovascular testing, has positioned this science at the center of its diagnostic platform. The company leverages epigenetics to reveal hidden heart disease risks that traditional genetic testing might miss. By analyzing epigenetic markers, Cardio Diagnostics can provide invaluable insight into the impact of an individual's lifestyle, behavior, and environment on their cardiovascular health.
Understanding the basic concept of epigenetics is key. Think of DNA as a massive instruction manual containing every gene a person could ever use. That manual does not change much over a lifetime. What does change is which pages get read, how often and how loudly. Epigenetics is essentially the mechanism that controls gene expression, and it can be influenced by factors such as diet, exercise, stress, and exposure to toxins.
Cardio Diagnostics' approach does more than pinpoint a problem, says CEO; it also provides some level of solution. By identifying epigenetic changes that contribute to heart disease risk, the company's tests can guide personalized interventions, such as lifestyle modifications or targeted therapies, to potentially reverse or mitigate those risks. This represents a shift from reactive to preventive cardiology.
The implications of this announcement are significant. Cardiovascular disease remains the leading cause of death globally, and traditional risk assessments often miss individuals who appear healthy but harbor hidden risks. Epigenetic testing could fill that gap, enabling earlier detection and more effective prevention. For investors, CDIO's focus on a novel biomarker class positions it in a growing market for precision medicine. The company's progress is detailed in its newsroom at https://ibn.fm/CDIO.
As with any forward-looking statements, risks and uncertainties remain, as outlined in the company's SEC filings. However, the potential of epigenetics to transform heart disease risk assessment is a development worth watching.
